ABVC - ABVC BioPharma, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

ABVC

ABVC BIOPHARMA, INC.

NASDAQ

$0.83

▲ UP 4.31% (0.03)

KEY STATISTICS

Market Cap$21.58 M

52w High$3.40

52w Low$0.71

Dividend Yield—

Frequency—

P/E-2.31

Volume94.04K

Shares Out.26.00M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Uttam Yashwant Patil

COMPENSATION 2026

Salary$200,000

Stock Awards$0

Incentive Plan Pay$0

All Other Comp.$22,023

Total$222,023

ABOUT

SECTOR

Healthcare

WENT PUBLIC

November 10, 2004

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

UPCOMING EARNINGS

DateNov 16, 2026

DayMonday

Rev. Est.$113.26K

NOV

MON

SPLIT RECORD

DATE	TYPE	RATIO
2023-07-25	Reverse	1:10
2019-05-20	Reverse	1:18
2019-05-08	Reverse	1:18
2016-04-11	Forward	157:50
2015-09-17	Reverse	1:5000
2015-08-13	Reverse	1:5000
2011-04-05	Reverse	1:5
2011-02-18	Reverse	1:5
2007-06-19	Forward	1573:1000

PRICE

$0.83 ▲ UP 4.31% (+$0.03)

OVERLAYS

About ABVC BioPharma, Inc.

https://www.abvcpharma.com ↗

ABVC BioPharma, Inc., a California-based clinical-stage biopharmaceutical company, develops therapies for unmet medical needs, including cancer, depression, ADHD, and retinal conditions, through multiple ongoing and completed clinical trials.

INDUSTRY

Biotechnology

A PRODUCT ABVC BIOPHARMA, INC. IS KNOWN FOR

Vitargus® (ABV-1701)

Vitargus® is a biodegradable vitreous substitute for ophthalmic surgery, offering a next-generation, potentially removable alternative to traditional materials for treating retinal detachment and vitreous hemorrhage.